Loading...
BVMF
PFRM3
Market cap162mUSD
Jul 09, Last price  
6.78BRL
1D
1.65%
1Q
-19.19%
Jan 2017
-14.29%
IPO
-70.48%
Name

Profarma Distribuidora de Produtos Farmaceuticos SA

Chart & Performance

D1W1MN
BVMF:PFRM3 chart
P/E
6.99
P/S
0.07
EPS
0.97
Div Yield, %
9.02%
Shrs. gr., 5y
Rev. gr., 5y
15.87%
Revenues
11.45b
+12.77%
1,728,608,0002,268,874,0002,535,516,0002,578,291,0002,626,119,0003,317,048,0003,233,057,0003,470,310,0003,449,124,0003,465,143,0004,084,669,0004,100,711,0004,271,127,0004,801,292,0005,481,341,0006,413,199,0007,816,218,0008,661,744,00010,153,623,00011,450,521,000
Net income
119m
+3.77%
-3,552,00047,032,00031,640,00053,152,00034,382,00026,420,00040,586,00020,353,000-52,117,000-21,182,000-48,963,000-112,720,000-9,734,00011,978,00052,334,00078,192,00080,874,00070,397,000114,579,000118,898,000
CFO
337m
-32.23%
-98,496,000-162,820,00011,027,00080,249,00044,404,00029,876,0008,934,000-90,024,00058,866,00059,265,000-107,293,000-51,826,000-55,845,000127,606,00039,344,000107,576,000126,322,000260,899,000497,088,000336,888,000
Dividend
Jan 02, 20260.31808 BRL/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1961 and headquartered in Rio de Janeiro, Brazil, Profarma Distribuidora de Produtos Farmacêuticos S.A. is a prominent player in the Brazilian healthcare market, focusing on both the wholesale and retail sales of pharmaceutical and hospital supplies. The company's operations are divided into distinct Distribution and Retail segments. Its comprehensive product offerings include a vast array of pharmaceuticals, such as brand-name drugs, generic alternatives, and over-the-counter medications. Profarma also supplies essential hospital products, including injectable and infusion therapies for specialized medical areas like oncology, endocrinology, rheumatology, infectology, and hematology. Furthermore, it provides specific treatments such as vaccines for conditions like influenza, HPV, meningitis, hepatitis, chickenpox, and dengue, alongside specialized medicines for rare and complex diseases. Beyond pharmaceuticals, the company distributes a wide selection of personal care, beauty, and cosmetic items. This category encompasses shampoos, conditioners, treatment creams, hair dyes, baby products like diapers, soaps, deodorants, oral care essentials, sunscreens, men's grooming products, cosmetics, makeup, and skincare. Profarma also features proprietary lines under the Nº21, GOnutri, and Bem Básico brands, offering exclusive hygiene and beauty products, vitamins, and workshop items. Complementing these, convenience goods such as food products, blood pressure monitors, and scales are also available. The company extends its services to include promotional and logistical support, implementation of marketing campaigns, product recall management, development of bespoke solutions for laboratories, and oversight of clinical procedures. As of December 31, 2019, Profarma's infrastructure boasted eleven strategically located distribution centers across several Brazilian states (Alagoas, Bahia, Espírito Santo, Goiás, Minas Gerais, Paraíba, Paraná, Pernambuco, Rio Grande do Sul, Rio de Janeiro, and São Paulo). Its retail footprint comprised approximately 196 stores operating under the Drogarias Tamoio, Drogasmil, Farmalife, and Rede Rosário banners, situated in the states of Rio de Janeiro, Goiás, Tocantins, Mato Grosso, and Distrito Federal.
IPO date
Oct 26, 2006
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT